The LRRK2 inhibitors (DNL201 and DNL151) developed by Denali Therapeutics seem to be designed specifically with the aim of restoring the LRRK-mediated lysosomal dysfunction in PD as stated in a Press release (https://www.globenewswire.com/news-release/2020/01/14/1970308/0/en/...sitive-Results-From-Its-LRRK2-Program-for-Parkinson-s-Disease.html), at the Denali-Therapeutics website (https://www.denalitherapeutics.com/pipeline), and the Denali Therapeutics’ January 2020 report (https://denalitherapeutics.gcs-web.com/node/7361/pdf). This evidence concerns the gene LRRK2 and Parkinson disease.